Med LifeBSE:M +0.53%90 EBITDA Margin % is 14.11% as of Mar. 2026, which is 8% above its 10-year median of 13.11. GuruFocus rates BSE:M with a GF Score™ of 90/100 and a GF Value™ of lei7.82 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Med Life ranks better than 56.89% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Med Life's EBITDA for the
three
months ended in Mar. 2026 was lei120 Mil. Med Life's Revenue for the
three
months ended in Mar. 2026 was lei853 Mil. Therefore, Med Life's EBITDA margin for the quarter that ended in Mar. 2026 was 14.11%.
Med Life (BSE:M) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Med Life EBITDA Margin % Related Terms
Med Life EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Med Life's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSE:M vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Med Life's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Med Life EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Med Life's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Med Life's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Med Life (BSE:M) has a EBITDA Margin % of 14.11% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Med Life and its competitors. This is near median its historical median of 13.11. Over the past decade, Med Life's EBITDA Margin % has ranged from 10.06 to 19.00. According to the industry distribution chart, Med Life ranks #288 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 43.1%.
Is Med Life's EBITDA Margin % too high?
Med Life's current EBITDA Margin % of 14.11% is near median its 10-year median of 13.11. Over the past 10 years, this metric has ranged from a low of 10.06 to a high of 19.00. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Med Life's value of 14.11% is 38.2% above this industry median. Based on the distribution chart, Med Life ranks #288 out of 668 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Med Life has a GF Score™ of 90/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Med Life's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Med Life ranks #288 out of 668 companies for EBITDA Margin %. This puts Med Life in the upper half of its industry. The industry median EBITDA Margin % is 10.21. Med Life's value of 14.11% is 38.2% above this benchmark. Historically, Med Life's own EBITDA Margin % has ranged from 10.06 to 19.00 over the past decade. While the company's 10-year median is 13.11 vs. the industry median of 10.21, Med Life has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Med Life's current EBITDA Margin % of 14.11% is 38.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Med Life and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Med Life's current EBITDA Margin % is 14.11%, which is near median its own 10-year median of 13.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Med Life stock overvalued right now?
Based on GuruFocus' analysis, Med Life (BSE:M) is currently considered Significantly Overvalued. The stock's GF Value™ is lei7.82, compared to a current price of lei11.36 — trading 45.3% above its estimated fair value. The current EBITDA Margin % is 14.11%, which is near median its 10-year median of 13.11 and 38.2% above the Healthcare Providers & Services industry median of 10.21. Med Life's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Med Life (BSE:M), the current EBITDA Margin % is 14.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Med Life (BSE:M) Overvalued in 2026?
Based on GuruFocus' analysis, Med Life stock appears to be overvalued.
The current stock price of lei11.36 is trading 45.3% above its estimated GF Value™ of lei7.82.
GuruFocus considers Med Life to be Significantly Overvalued.
Key valuation signals for BSE:M:
EBITDA Margin %: 14.11% (near median its 10-year median of 13.11)
GF Value™: lei7.82 vs. price of lei11.36 (45.3% above fair value)
Industry Position: 38.2% above the Healthcare Providers & Services median (#288 of 668)
No single metric tells the full story. See the BSE:M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Med Life SA is a healthcare provider in Romania. The Company's activity resides in the performance of healthcare services activities through medical centres with national coverage. It is engaged in the provision of rendering of medical services, rental of medical facilities and acquisition of materials and commodities. The company provides medical service through Hyper clinics in Arad, Bucharest, Braila, Brasov, Cluj, Constanta, Craiova, Galati, Iasi, Oradea, Ploiesti, Sibiu and Timisoara; Clinics, hospitals located in Bucharest, Arad, Sibiu, Brasov, Cluj and Ploiesti, Laboratories, Pharmacies and Dental Clinics.
90GF Score
Get the complete analysis for BSE:M
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSE:M has been successfully added to your 
